Android app on Google Play

Baird Starts Idenix Pharmaceuticals Inc. (IDIX) at Neutral; No Great Pipeline but Patents Could Have Value

February 11, 2013 4:26 PM EST Send to a Friend
Get Alerts IDIX Hot Sheet
Price: $24.50 --0%

Rating Summary:
    2 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 2
Trade IDIX Now!
Join SI Premium – FREE
After the close, Baird initiated coverage on Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) with a Neutral and $5 price tarrget.

With a focus on Hepatitis C, the firm does not find the company's pipeline particularly compelling, from an investment standpoint. That said, they view the company's patent estate as a wild card with a potential for economic interest in Gilead's (NASDAQ: GILD) Hep C programs.

For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.

Shares of Idenix Pharmaceuticals Inc. closed at $4.73 yesterday.




You May Also Be Interested In


Related Categories

New Coverage

Related Entities

Robert W Baird

Add Your Comment